{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:50:22Z","timestamp":1792479022915,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jid.2022.12.028","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T07:26:28Z","timestamp":1697786788000},"page":"500-508.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Eukaryotic Initiation Factor 4E (eIF4E) as a Target of Anti-Psoriatic Treatment"],"prefix":"10.1016","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7330-1854","authenticated-orcid":false,"given":"Nicole","family":"Golob-Schwarzl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8452-0879","authenticated-orcid":false,"given":"Johannes","family":"Pilic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6218-2792","authenticated-orcid":false,"given":"Theresa","family":"Benezeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9505-6271","authenticated-orcid":false,"given":"Natalie","family":"Bordag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5165-0407","authenticated-orcid":false,"given":"Clemens","family":"Painsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7777-9444","authenticated-orcid":false,"given":"Peter","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2022.12.028_bib1","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.56991","article-title":"Dithranol targets keratinocytes, their crosstalk with neutrophils and inhibits the IL-36 inflammatory loop in psoriasis","volume":"9","author":"Benezeder","year":"2020","journal-title":"eLife"},{"key":"10.1016\/j.jid.2022.12.028_bib2","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/j.1460-2075.1996.tb00398.x","article-title":"Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation","volume":"15","author":"Beretta","year":"1996","journal-title":"EMBO J"},{"key":"10.1016\/j.jid.2022.12.028_bib3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd4505","article-title":"Targeting the translation machinery in cancer","volume":"14","author":"Bhat","year":"2015","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"10.1016\/j.jid.2022.12.028_bib4","first-page":"74","article-title":"EIF4E-mediated translational control of cancer incidence","volume":"1849","author":"Bitterman","year":"2015","journal-title":"BBA Gene Regul Mech"},{"key":"10.1016\/j.jid.2022.12.028_bib5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2022.12.028_bib6","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.jaci.2021.11.001","article-title":"Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis","volume":"149","author":"Catlett","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2022.12.028_bib7","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/s41591-018-0217-1","article-title":"Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma","volume":"24","author":"Cerezo","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jid.2022.12.028_bib8","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.3390\/molecules25081822","article-title":"Combination therapy of acarbose and cyclosporine a ameliorates imiquimod-induced psoriasis-like dermatitis in mice","volume":"25","author":"Chen","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.jid.2022.12.028_bib9","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s13555-021-00596-8","article-title":"Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with Janus kinase 1\/2\/3 inhibitors","volume":"11","author":"Chimalakonda","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jid.2022.12.028_bib10","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00432-010-0902-z","article-title":"Direct inhibition of eIF4E reduced cell growth in endometrial adenocarcinoma","volume":"137","author":"Choi","year":"2011","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.jid.2022.12.028_bib11","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1038\/jid.2013.3","article-title":"1alpha,25- dihydroxyvitamin-D3\u20133-bromoacetate regulates AKT\/mTOR signaling cascades: a therapeutic agent for psoriasis","volume":"133","author":"Datta Mitra","year":"2013","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2022.12.028_bib12","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1038\/sj.onc.1207545","article-title":"eIF-4E expression and its role in malignancies and metastases","volume":"23","author":"De Benedetti","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.jid.2022.12.028_bib13","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.chembiol.2014.01.011","article-title":"MAP kinase-interacting kinases emerging targets against cancer","volume":"21","author":"Diab","year":"2014","journal-title":"Chem Biol"},{"key":"10.1016\/j.jid.2022.12.028_bib14","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000515763","article-title":"Long-term effectiveness and drug survival of apremilast in treating psoriasis: a real-world experience","volume":"238","author":"Distel","year":"2022","journal-title":"Dermatology"},{"key":"10.1016\/j.jid.2022.12.028_bib15","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/ijc.30199","article-title":"Modulation of tumor eIF4E by antisense inhibition: a phase I\/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer","volume":"139","author":"Duffy","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jid.2022.12.028_bib16","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1001\/archotol.129.7.794","article-title":"Prognostic factors and outcome for nasopharyngeal carcinoma","volume":"129","author":"Farias","year":"2003","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.jid.2022.12.028_bib17","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.4161\/cc.8.16.9301","article-title":"Cap in hand: targeting eIF4E","volume":"8","author":"Fischer","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.jid.2022.12.028_bib18","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.tiv.2012.08.006","article-title":"Skin phototoxicity of cosmetic formulations containing photounstable and photostable UV-filters and vitamin A palmitate","volume":"27","author":"Gaspar","year":"2013","journal-title":"Toxicol In\u00a0Vitro"},{"key":"10.1016\/j.jid.2022.12.028_bib19","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1146\/annurev.biochem.68.1.913","article-title":"eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation","volume":"68","author":"Gingras","year":"1999","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.jid.2022.12.028_bib20","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1158\/0008-5472.CAN-08-3472","article-title":"eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival","volume":"69","author":"Graff","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.jid.2022.12.028_bib21","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1172\/JCI32044","article-title":"Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity","volume":"117","author":"Graff","year":"2007","journal-title":"The Journal of clinical investigation"},{"key":"10.1016\/j.jid.2022.12.028_bib22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.7150\/ijbs.8.228","article-title":"The pro-inflammatory role of TGFbeta1: a paradox?","volume":"8","author":"Han","year":"2012","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.jid.2022.12.028_bib23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10549-013-2671-2","article-title":"Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment","volume":"141","author":"Heikkinen","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jid.2022.12.028_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0225537","article-title":"eIF4E and 4EBP1 are prognostic markers of head and neck squamous cell carcinoma recurrence after de finitive surgery and adjuvant radiotherapy","volume":"14","author":"Huang","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jid.2022.12.028_bib25","doi-asserted-by":"crossref","DOI":"10.1172\/JCI140752","article-title":"VInhibiting the MNK1\/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses","volume":"131","author":"Huang","year":"2021","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jid.2022.12.028_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081669","article-title":"Targeting eukaryotic translation in mesothelioma cells with an eIF4Especific antisense oligonucleotide","volume":"8","author":"Jacobson","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jid.2022.12.028_bib27","doi-asserted-by":"crossref","unstructured":"Jasani N, Desai B, Betzu JM, Dichwalkar T, Bapat S, Rajadhayksha VJ, et\u00a0al Potent anticancer activity of an orally bioavailable small molecule, ON 013100, and its water soluble derivative, briciclib, a clinical-stage eIF4E-targeted agent. In: Proceedings of the 106th annual meeting of the American Association for Cancer Research. Cancer Res 2015;2015:75.","DOI":"10.1158\/1538-7445.AM2015-1649"},{"key":"10.1016\/j.jid.2022.12.028_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13671-020-00326-x","article-title":"Deucravacitinib for psoriasis","volume":"10","author":"Kim","year":"2021","journal-title":"Curr Derm Rep"},{"key":"10.1016\/j.jid.2022.12.028_bib29","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/j.1365-2133.2009.09303.x","article-title":"The expression and phosphorylation of eukaryotic initiation factor 4E are increased in lesional psoriatic skin","volume":"161","author":"Kjellerup","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2022.12.028_bib30","first-page":"280","article-title":"The impact of psoriasis on quality of life: results of a 1998 national psoriasis foundation patient-membership survey","volume":"137","author":"Krueger","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2022.12.028_bib31","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2022.12.028_bib32","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000323408","article-title":"Calcipotriol plus betamethasone dipropionate gel compared with tacalcitol ointment and the gel vehicle alone in patients with psoriasis vulgaris: a randomized, controlled clinical trial","volume":"222","author":"Langley","year":"2011","journal-title":"Dermatology"},{"key":"10.1016\/j.jid.2022.12.028_bib33","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1038\/sj.emboj.7600183","article-title":"Latent TGF\u03b21 overexpression in keratinocytes results in a severe psoriasis-like skin disorder","volume":"23","author":"Li","year":"2004","journal-title":"EMBO J"},{"key":"10.1016\/j.jid.2022.12.028_bib34","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1017\/erm.2015.20","article-title":"Targeting translation: EIF4E as an emerging anticancer drug target","volume":"18","author":"Lu","year":"2016","journal-title":"Expert Rev Mol Med"},{"key":"10.1016\/j.jid.2022.12.028_bib35","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","article-title":"AKT\/PKB signaling: navigating downstream","volume":"129","author":"Manning","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.jid.2022.12.028_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/cshperspect.a033092","article-title":"Protein synthesis initiation in eukaryotic cells","volume":"10","author":"Merrick","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.jid.2022.12.028_bib37","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4161\/cbt.4.3.1504","article-title":"Growth inhibition of head and neck squamous carcinoma cells by small interfering RNAs targeting eIF4E or cyclin D1 alone or combined with cisplatin","volume":"4","author":"Oridate","year":"2005","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.jid.2022.12.028_bib39","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/j.jid.2018.04.019","article-title":"Ixekizumab pharmacokinetics, Anti-Drug antibodies, and efficacy through 60 weeks of Treatment of Moderate to Severe Plaque Psoriasis","volume":"138","author":"Reich","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2022.12.028_bib40","doi-asserted-by":"crossref","first-page":"6869","DOI":"10.1007\/s00018-021-03938-z","article-title":"Control of the eIF4E activity: structural insights and pharmacological implications","volume":"78","author":"Romagnoli","year":"2021","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jid.2022.12.028_bib41","doi-asserted-by":"crossref","first-page":"572","DOI":"10.2340\/00015555-2011","article-title":"Treatment satisfaction of patients with psoriasis","volume":"95","author":"Schaarschmidt","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jid.2022.12.028_bib42","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/exd.12779","article-title":"8-methoxypsoralen plus UVA (PUVA) therapy normalizes signalling of phosphorylated component of mTOR pathway in psoriatic skin of K5.hTGFbeta1 transgenic mice","volume":"24","author":"Shirsath","year":"2015","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jid.2022.12.028_bib44","article-title":"Involvement of IL-9 in Th17-associated inflammation and angiogenesis of psoriasis","volume":"8","author":"Singh","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jid.2022.12.028_bib46","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.cell.2009.01.042","article-title":"Regulation of translation initiation in eukaryotes: mechanisms and biological targets","volume":"136","author":"Sonenberg","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.jid.2022.12.028_bib47","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/lary.22144","article-title":"Analysis of eIF4E and 4EBP1 mRNAs in head and neck cancer","volume":"121","author":"Sunavala-Dossabhoy","year":"2011","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jid.2022.12.028_bib48","doi-asserted-by":"crossref","first-page":"9089","DOI":"10.1038\/s41598-019-45626-w","article-title":"Small molecule IL-36\u03b3 antagonist as a novel therapeutic approach for plaque psoriasis","volume":"9","author":"Todorovi\u0107","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jid.2022.12.028_bib49","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/bjd.20083","article-title":"Efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study","volume":"185","author":"Van Voorhees","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2022.12.028_bib50","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.3892\/ijo.2015.3201","article-title":"Knockdown of eIF4E suppresses cell proliferation, invasion and enhances cisplatin cytotoxicity in human ovarian cancer cells","volume":"47","author":"Wan","year":"2015","journal-title":"Int J Oncol"},{"key":"10.1016\/j.jid.2022.12.028_bib51","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s12032-012-0400-z","article-title":"EIF4E over-expresses and enhances cell proliferation and cell cycle progression in nasopharyngeal carcinoma","volume":"30","author":"Wu","year":"2013","journal-title":"Med Oncol"},{"key":"10.1016\/j.jid.2022.12.028_bib52","first-page":"1132","article-title":"Expression and its clinical significance of eIF4E in non-small cell lung cancer","volume":"13","author":"Zhang","year":"2010","journal-title":"Chin J Lung Cancer"},{"key":"10.1016\/j.jid.2022.12.028_bib53","article-title":"eIF4E overexpression is associated with poor prognoses of ovarian cancer","volume":"2020","author":"Zheng","year":"2020","journal-title":"Anal Cell Pathol (Amst)"},{"key":"10.1016\/j.jid.2022.12.028_bib54","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1007\/s12032-010-9630-0","article-title":"Knockdown of eIF4E suppresses cell growth and migration, enhances chemosensitivity and correlates with increase in Bax\/Bcl-2 ratio in triple-negative breast cancer cells","volume":"28","author":"Zhou","year":"2011","journal-title":"Med Oncol"},{"key":"10.1016\/j.jid.2022.12.028_bib55","first-page":"1343","article-title":"Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis","volume":"20","author":"Zimmer","year":"2000","journal-title":"Anticancer Res"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X23029172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X23029172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T02:03:33Z","timestamp":1740794613000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X23029172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0022202X23029172"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2022.12.028","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eukaryotic Initiation Factor 4E (eIF4E) as a Target of Anti-Psoriatic Treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2022.12.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}